Track market-moving stories before they get noisy

In Brief

Posted:

Image Credits:Brian Heater / TechCrunch Apple will announce a new smart home hub on Tuesday called the HomeView, according to Bloomberg’s Mark Gurman.

Over the past couple of years, we’ve seen There have been multiple reports that Apple was working on a new smart home product, but now it seems the product has a name and a launch date. Gurman described the HomeView as a Siri-powered device with a display and an A18 chip, allowing customers to control their other smart home devices.

The HomeView will reportedly be available in two models — one designed for countertops and the other to be mounted on walls. 

This would be Apple’s most serious bet on the smart home to date, after it failed to get much traction for its HomeKit software framework or its HomePod smart speaker. 

Gurman reports that on Tuesday, Apple will also be unveiling updated versions of two other home devices, namely the Apple TV set-top box and the HomePod mini. Earlier this week, he said that Apple plans to announce a partnership with LG to create a smart lock, a thermostat, and a doorbell.

Topics

Subscribe for the industry’s biggest tech news

Latest in Hardware

Amazon is in talks to acquire Decart, a fast-growing artificial intelligence (AI) company. According to the WSJ, Amazon is planning to buy the company in a $7 billion deal, marking a big jump from its last funding round in May, which valued it at $4 billion.

Neither side has confirmed the deal, and according to the WSJ, talks could still fall apart or another suitor can come up. 

The company has been growing fast, helped by the adequate capital from top venture capital firms like Sequoia Capital, Benchmark, Radical Ventures, Zeev Ventures, Nvidia, and Toyota Ventures. 

Decart is creating software that makes it easier for developers to switch between different AI chips, a capability that has become more popular this year. It is also known for models that generate interactive video and simulated environments as one interacts with them. These models are known as Lucy and Oasis. 

The potential acquisition comes a few months after Amazon Web Services gave Decart an early access to its Tranium chip. It was highly impressed by the founders, according to the WSJ.

The report comes at a time when Amazon is aiming to become a major player in various areas in the AI space. It is one of the biggest shareholders in Anthropic, a company that will launch an IPO at a $2 trillion valuation. 

It has also built Tranium, its chips that it hopes will be bigger competitors to those made by Nvidia. Most importantly, Amazon is becoming a major infrastructure provider for companies in the AI industry. It is in the process of spending $220 billion in capital expenditure this year. 

The report also comes at a time when large companies are scooping promising AI startups. As we reported earlier, Nvidia is in talks to acquire Reflection AI, a company that makes open-source AI models. If the deal goes through, it will be the biggest one it has executed. It recently announced a plan to acquire Hugging Face for $13 billion. 

SpaceX recently acquired Cursor for $60 billion. Meta Platforms also made a bid for Manus, before abandoning it amid regulatory concerns.  AMD recently acquired World Labs for $8.2 billion, while Stripe acquired OpenRouter for $7.2 billion.

NEW YORK, Oct. 11, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Hyliion Holdings Corp. (NYSE: HYLN) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Hyliion securities between May 12, 2026 and June 23, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/cases/hyliion-holdings-corp-hyln-class_action_lawsuit.

Hyliion Case Details

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that:

(1) in order to cause rapid price appreciation in Hyliion stock, Defendants announced a deal with an entity that was very recently formed and does not appear to have any actual business operations;(2) Thomas Healy, the Company's Chief Executive Officer (CEO), and Jon Panzer, the Company's Chief Financial Officer (CFO), timed the announcement and the foregoing price appreciation to insider trading; and(3) as a result, defendants' statements about Hyliion's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
What's Next for Hyliion Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/cases/hyliion-holdings-corp-hyln-class_action_lawsuit. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in Hyliion you have until October 27, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to Hyliion Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Hyliion Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

October 2025 was arguably the best month for U.S. rare-earth stocks. Indeed, both of the top two rare-earth miners in the U.S. -- MP Materials (MP +0.00%) and USA Rare Earth (USAR -0.55%) -- were on an absolute tear, with both stocks up over 45% from the start of the month to Oct. 14, 2025. The geopolitical climate looked favorable to rare-earth companies, China was tightening its grip on critical minerals, and the White House appared dead-set on building a domestic rare-earth supply chain.

What could go wrong, right?

Fast-forward to today, and rare-earth stocks have not delivered on the sky-high expectations investors have had for them. Both MP Materials and USA Rare Earth are down year over year as I write this, as is the VanEck Rare Earth and Strategic Metals ETF (REMX +0.64%).

Although all three are in the red, USA Rare Earth has taken the biggest hit. In fact, an investment in USA Rare Earth last October would have been cut in half.

Image source: Getty Images.

A $10,000 investment in USA Rare Earth would be worth this much today On Oct. 6, 2025, the closing price for USA Rare Earth was about $26. Today, one year later, USA Rare Earth is trading for about $14 a share as I write this. Put differently, a $10,000 in USA Rare Earth stock would be worth about $5,300 today, a loss of roughly 47%.

Premium Feature

Moneyball Superscore

50/100

Today's Change

(

-0.55

%) $

-0.07

Current Price

$

12.56

What happened? Well, USA Rare Earth was riding a wave of investor enthusiasm last October. The Department of Defense had recently invested $400 million in MP Materials, and China was tightening restrictions around rare-earth exports. True, the former bit helped its rival more than itself, but news of Washington's broad support of the rare-earth industry lifted both companies on Wall Street.

At the same time, USA Rare Earth had just appointed Barbara Humpton, former CEO of Siemens USA, as its new CEO last September. Humpton revealed that the company was in talks with the White House, which fueled speculation that USA Rare Earth would receive federal support next.

Things were looking good. Then, things started going south.

In late October, the U.S. and China reached a trade truce that paused China's newest rare-earth export restrictions. All of a sudden, much of the urgency that had shaped USA Rare Earth's bull case had lost its tension.

Meanwhile, investors were waking up to just how much USA Rare Earth would need to turn its mine-to-magnet ambitions into a thriving business. Indeed, this was especially clear in January 2026, when USA Rare Earth raised $1.5 billion by selling around 70 million new shares.

Is USA Rare Earth worth a large investment today? I wouldn't put a big investment into USA Rare Earth today. Mining is an expensive business, and even with federal support in its back pocket, USA Rare Earth has a long way to go before it will produce rare-earth magnets. In the meantime, plenty of factors could derail its ambitions or limit its growth, not the least of which is the enormous amount of capital required to build mines and magnet factories.

At this point, most investors would probably be better off with a rare-earth exchange-traded fund (ETF) that holds shares of multiple companies rather than investing directly in USA Rare Earth.

Centrus Energy's (LEU +0.25%) stock closed at a 52-week high of $464.25 per share on Oct. 16, 2025. Today, it trades at about $143. Let's see why this nuclear energy stock shed 69% of its value -- and if its growing backlog makes it a contrarian investment today.

What does Centrus do? Centrus is one of the few U.S. companies licensed to sell low-enriched uranium (LEU), the most commonly used fuel in commercial nuclear reactors. It's also the only public U.S. company that produces high-assay low-enriched uranium (HALEU) for next-gen nuclear reactors.

Image source: Getty Images.

Centrus originally enriched its own LEU on a commercial scale, but it shut down its aging plants 13 years ago when it became cheaper to import and resell LEU from overseas to U.S. utilities. But over the past few years, the sanctions against Russia and the U.S. drive toward energy independence prompted Centrus to restart its domestic enrichment strategy.

Centrus began producing HALEU in the U.S. three years ago and aims to restart its LEU enrichment operations in Ohio by the end of the decade. By the end of the second quarter of 2026, its total backlog of LEU and HALEU orders had swelled to $4.5 billion. That's equivalent to 9.5 times its projected revenue for 2026.

Today's Change

(

0.25

%) $

0.35

Current Price

$

142.44

Why did Centrus' stock pull back? Centrus might initially seem a no-brainer play on the resurgent nuclear market, which is benefiting from new decarbonization initiatives and the growth of the cloud and AI markets.

But from 2025 to 2028, analysts expect Centrus' revenue to decline from $449 million to $443 million, while its net income slides from $78 million to $50 million.

Centrus' backlog is robust, but it won't convert most of those orders into revenue until the late 2020s and the 2030s. The U.S. will also fully ban Russian uranium imports by 2028, before Centrus can fully restart its domestic enrichment operations at a commercial scale. Those delays and supply constraints will likely throttle its near-term revenue growth.

At the same time, Centrus must increase its capex to accelerate its domestic enrichment plans. That pressure will squeeze its near-term earnings, while rising interest rates will make it more expensive to issue fresh debt. All of those challenges caused its stock to pull back, but it still looks expensive at 50 times next year's earnings.

Centrus' stock should eventually recover after it completes its capital-intensive transformation, but it doesn't look like a bargain yet. Investors who want to profit from the nuclear market's growth should probably stick with safer and more diversified stocks instead.

Leo Sun has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Singapore has built a reputation as one of the friendlier places on earth for digital assets. That friendliness, it turns out, has limits.

The Monetary Authority of Singapore (MAS) has voiced serious concerns about decentralized crypto products. It is paying particular attention to highly leveraged perpetual futures platforms, and it has now named one of the biggest of them.

On June 26, 2026, MAS added Hyperliquid to its Investor Alert List. The platform is operated by Hyperliquid Labs, which is registered in Singapore.

What MAS actually flagged MAS uses its Investor Alert List to flag entities to the public. Hyperliquid landed there because of its decentralized structure, which the regulator considers to sit outside its oversight.

The regulator also pointed out that Hyperliquid is not regulated in any major jurisdiction.

Hyperliquid Labs has confirmed it is registered in Singapore. It has also stated that it is not licensed by MAS.

Advertisement

Why perpetual futures are the pressure point Perpetual futures, or “perps,” are derivatives that let traders bet on an asset’s price without ever holding it. Unlike traditional futures, they have no expiry date, so positions can stay open indefinitely.

Consumer advocates have described leveraged perps platforms as “the most dangerous product in crypto.”

MAS has been careful to draw a line here. It distinguishes the institutional perpetual futures offered on SGX, Singapore’s exchange, from what Hyperliquid offers. The regulator’s message is that the product type alone is not the issue. Who is trading it, under what rules, and with what protections is what counts.

MAS has also stressed that crypto trading carries high risks for the general public.

The “techno-anarchism” problem A Bloomberg opinion piece captured the broader mood among regulators. It described growing apprehension about the “techno-anarchism” of recent crypto products.

The Hyperliquid case shows how awkward this gets in practice. A company is registered in Singapore, yet the product it is associated with operates in a way MAS says falls beyond its reach.

Singapore’s balancing act MAS continues to champion tokenization and institutional activity in the sector while focusing on curbing the risks that come from retail speculation.

Singapore’s framework requires digital token service providers serving overseas clients to obtain a license. Approvals under the 2025 regulations have been limited.

MAS Managing Director Chia Der Jiun has emphasized trust and risk management in recent remarks. He has highlighted the intersection of AI and digital asset trading as an area needing attention.

What this means for traders and platforms The most immediate effect is reputational. An investor alert from a respected regulator is not a ban, but it is the kind of label that compliance teams, banks and institutional partners tend to notice.

The research findings suggest MAS’s stance could signal a more cautious posture among global regulators. If so, similar decentralized perps platforms may face increased scrutiny elsewhere.

By separating SGX’s institutional perps from Hyperliquid’s offerings, MAS is effectively endorsing one model of leveraged trading while warning against another.

Disclosure: This article was edited by John Chen. For more information on how we create and review content, see our Editorial Policy.

The Liquid Network is running again, but nobody can cash out. Peg-outs, the process of turning Liquid Bitcoin (L-BTC) back into real Bitcoin, remain suspended while the sidechain’s reserve sits about 603 BTC short, according to The Defiant.

Liquid says redemptions will not return until the reserve fully backs every L-BTC in circulation and its security reviews are complete.

How a software bug drained the reserve The trouble began on September 6, 2026. A bug in Elements, the software that powers Liquid, allowed someone to create and redeem L-BTC without authorization.

Approximately 3,996 to 4,000 BTC left the federation reserve. That haul was valued at around $320 million at the time.

The federation reserve had held roughly 4,205 BTC before the exploit. At the worst point of the crisis, it was down to just 197 BTC.

White-hat actors returned roughly 3,400 BTC by September 7, about a day after the drain.

That recovery still left between 598 and 603 BTC unreturned. Around mid-September, the reserve was reportedly covering about 86% of outstanding L-BTC supply.

The signing keys held by federation members were not compromised. Neither was SideSwap’s Peg-out Authorization Key.

What is working and what is not Liquid restarted normal block production and user transactions on September 10, 2026. People can send and receive L-BTC inside the network again.

As of October 11, 2026, peg-outs remain on hold. Liquid has tied a restart to several conditions.

Full restoration of 1:1 BTC backing for L-BTC Upgrades to the Elements software Completed security audits Changes to key management, notably a move to cold storage Blockstream CEO Adam Back has assured stakeholders that the 1:1 peg will ultimately be covered. No specific date for resuming redemptions appears in the available reporting.

Other assets issued on Liquid escaped the damage. USDT and tokenized real-world assets on the network were not disrupted and have returned to normal operations.

Background: what a federated sidechain actually is Liquid is a Bitcoin sidechain managed by Blockstream. Users lock BTC with a federation, a group of members who jointly control the reserve through multisig. In return, they receive L-BTC, which is meant to be redeemable one-for-one for the Bitcoin held in that reserve.

The arrangement is called a two-way peg. Bitcoin goes in, L-BTC comes out, and the reverse should work just as smoothly.

That design depends on two things holding firm: the integrity of the multisig reserve and the reliability of the software enforcing the peg. In September, the second one failed.

What this means for L-BTC holders and the sidechain model For anyone holding L-BTC, the immediate issue is liquidity. A token that cannot be redeemed for its underlying asset behaves differently from one that can, even if the issuer promises full repayment.

The 86% coverage figure frames the risk. Most of the backing is there, but the gap is real, and closing it depends on the shortfall being filled through means the reporting does not specify.

Liquid’s insistence on full backing before reopening redemptions is the cautious path. Restarting peg-outs at 86% coverage could invite a rush for the exits, leaving the last redeemers with nothing to claim.

The planned move toward cold storage also signals a shift in operational priorities.

Disclosure: This article was edited by Estefano Gomez. For more information on how we create and review content, see our Editorial Policy.

Cover image via U.Today Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The XRP Ledger eyes crucial fixes and improvements over the next few days. According to XRPScan data, fixCleanup3_4_0 began its two-week activation window on October 5, 2026, with the earliest activation date being 9:34 AM UTC on October 23, 2026.

Validator support for the fixCleanup3_4_0 amendment must stay above 80% for it to launch. If it slips to 80% or lower even once, the amendment is rejected and the 14-day timer starts over.

This fixCleanup3_4_0 amendment is a collection of fixes for Single Asset Vaults, the Lending Protocol, Automated Market Makers, the permissioned DEX, trust lines, NFTs, MPTs, Escrow, Sponsorship, transaction signing, and permission delegation.

HOT Stories

You Might Also Like

FixCleanup3_4_0, which bundles amendment-gated fixes, was shipped in Version 3.4.0 of xrpld, the reference server implementation of the XRP Ledger protocol, and entered voting on September 17, 2026. The amendment has 81.25% consensus, with 26 out of 32 validators having voted for it.

The Permission Delegation and Batch amendments went live as a key milestone in the past week. The fixCleanup3_4_0 amendment is essential for Permission Delegation, as until it is enabled, users would not be able to delegate the PaymentBurn granular permission. Before the fix, a delegate with the PaymentBurn granular permission could also mint new fungible tokens (trust line tokens or MPTs) in certain circumstances. Other granular permissions are unaffected.

Wide-ranging protocol fixes anticipatedThis fixCleanup3_4_0 amendment is a collection of fixes: it excludes deleted domain offers from the Permissioned DEX invariant, so replacing an offer in one domain with an offer in another no longer triggers a violation.

You Might Also Like

The fix prevents 'AMMClawback' from silently recovering zero when integer MPT rounding floors the amount, instead of burning the holder's LP tokens for nothing, and allows AMMClawback to bypass the owner-reserve check when it must auto-create the paired asset holding, so a compliance clawback is not blocked or vetoed by reserve requirements.

The fix rejects fake-XRP NFT offer amounts, exempts an IOU issuer from their own global freeze when creating an NFToken offer denominated in their own currency, and tightens permissioned DEX domain checks. It also recycles the escrow owner reserve in EscrowCancel and EscrowFinish, so returning IOUs to an owner at the reserve boundary no longer fails. It adds precision and rounding fixes across VaultDeposit, VaultWithdraw, and VaultClawback, so a vault's tracked total assets, available assets, and share supply stay consistent.

The fix refines freeze, authorization, credential, and destination handling for Single Asset Vaults and the Lending Protocol; for example, exempting loan defaults from asset freeze, refusing pseudo-accounts where they cannot participate, and validating permissioned-domain withdrawal destinations and rejecting 'PaymentBurn' payments that cross a zero balance.

Starknet's native token $STRK surged over 100% on the week after the Ethereum Layer 2 announced it is actively considering a move to become an independent Layer 1 blockchain, with a 2027 quantum-resistance target.

@Starknet's native token $STRK has surged more than 107% over the past week, making it one of the standout performers in the crypto market. The catalyst: a statement from the @Starknet team saying it is actively weighing a transition from an Ethereum Layer 2 network into a fully independent Layer 1 blockchain.

The Announcement That Moved Markets The announcement came on October 8, 2026, when Starknet said on its official account: The statement was enough to send $STRK to its highest level in nine months.

It is worth noting that no final decision has been made.

What It Could Mean for the Broader L2 Ecosystem The market reaction has been striking enough to raise a broader question: could other @Ethereum L2 projects follow suit? The momentum around $STRK suggests investor appetite for L2 networks that signal a path toward greater protocol independence.

Traders should also keep an eye on near-term supply dynamics. Whether strong trading volumes can absorb that additional supply will be a key test of whether the rally has real staying power.

Sources:
STRK Token Outperforms Bitcoin to Hit 9-Month High, Yahoo Finance
STRK rallies as Starknet weighs a move from Ethereum layer 2 to its own layer 1, Crypto Briefing
STRK Price Rises as Starknet Targets Quantum-Resistant L1 by 2027, Crypto Times

New Phase 3 AFFIRM data show higher rates of clinical and endoscopic response in Crohn's disease patients treated with subcutaneous SKYRIZI versus placebo across all efficacy endpoints and observed subgroups New open-label extension analyses demonstrate sustained endoscopic outcomes over time with SKYRIZI, even in patients with complex disease characteristics and prior treatment exposure In real-world studies, patients with advanced Crohn's disease achieved disease control with RINVOQ, highlighting its potential benefit for difficult-to-treat patients The breadth of scientific abstracts and oral presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting demonstrates AbbVie's pursuit to address the complexities of inflammatory bowel disease care , /PRNewswire/ -- AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting in Nashville, Tennessee, Oct. 9-14. Data presented will include newly unveiled AFFIRM results showing efficacy for SKYRIZI® (risankizumab-rzaa) in advanced therapy-naïve Crohn's disease (CD) patients, open-label extension analyses demonstrating long-term outcomes with SKYRIZI in difficult-to-treat IBD and growing real-world evidence supporting RINVOQ® (upadacitinib) in advanced CD.

"People living with IBD want treatments that meaningfully reduce the burden of their disease," said Ryan DeMasi, M.D., vice president, global medical affairs, immunology, AbbVie. "Our presence at ACG reflects AbbVie's drive, as a leader in IBD, to provide what matters most to patients — therapies that perform over time and against the most complicated drivers of disease."

The ACG conference agenda is available here. Select AbbVie oral and poster presentations are highlighted below:

Clinical Remission and Endoscopic Outcomes With Subcutaneous SKYRIZI

Title

Description

Session Details

Efficacy and Safety of
Risankizumab
Subcutaneous Induction and
Maintenance in Patients
With Moderately to Severely
Active Crohn's Disease:
Results From the Phase 3
AFFIRM Study

Results from the Phase 3 AFFIRM trial
showed subcutaneous risankizumab
achieved significantly higher rates of clinical     
remission and endoscopic response versus
placebo at Week 12, with rates of all
endpoints remaining numerically higher
through Week 24 among clinical
responders.

Tuesday,
October 13

2:15 PM – 2:25 PM CDT 

Oral Presentation 37

Comparative Efficacy of
Subcutaneous
Risankizumab Versus
Guselkumab as Induction 
Therapy in Patients With
Moderately to Severely
Active Crohn's Disease: An 
Anchored Matching-Adjusted     
Indirect Comparison

New indirect comparative analyses showed
subcutaneous risankizumab achieved
significantly higher rates of endoscopic
response versus guselkumab during
induction in patients with moderately to
severely active Crohn's disease.

Tuesday,
October 13

10:30 AM – 4:00 PM CDT     

Poster P5748

Multiyear Endoscopic Healing With SKYRIZI in Patients With Complex Disease Characteristics and Prior Treatment Exposure

Title

Description

Session Details

Efficacy of Risankizumab by
Crohn's Disease Location:
Results From 144 Weeks of
the FORTIFY Open-Label
Extension Study

New analyses from the Phase 3 FORTIFY
open-label extension study demonstrated
sustained clinical and endoscopic outcomes     
with risankizumab through 144 weeks of
treatment across ileal, colonic and
ileocolonic Crohn's disease. Clinical and
endoscopic remission rates were generally
maintained or improved over time across
disease locations.

Sunday,
October 11

3:30 PM – 7:00 PM CDT

Poster P1061

Risankizumab for Fistulizing
Crohn's Disease: Post Hoc
Analysis of Up to 5 Years of
Treatment From the
FORTIFY Open-Label
Extension

Data from the Phase 3 FORTIFY open-
label extension study showed that 74.5% of
patients with fistulizing Crohn's disease
achieved no draining fistulas after five years
of treatment with risankizumab.

Sunday,
October 11

3:30 PM – 7:00 PM CDT

Poster P1058

Efficacy of Risankizumab by
Crohn's Disease Location
Through 148 Weeks of
Treatment: Results from the
SEQUENCE Open-Label
Extension Study

New analyses from the ongoing
SEQUENCE study demonstrated durable
clinical and endoscopic efficacy with
risankizumab through nearly three years of
treatment in patients with moderately to
severely active Crohn's disease following
anti-TNF failure. Endoscopic outcomes
among patients with ileal disease continued
to improve over time and became
comparable to outcomes observed across
other disease locations by Week 148.

Sunday,
October 11

3:30 PM – 7:00 PM CDT

Poster P1060

Sustained Clinical and
Endoscopic Improvements
With up to 3 Years of
Risankizumab Maintenance
Treatment in Patients With
Moderate to Severe
Ulcerative Colitis Regardless     
of the Number of Prior
Advanced Therapy
Exposures 

New analyses from the ongoing
COMMAND open-label extension study
demonstrated sustained clinical and
endoscopic improvements with
risankizumab through three years of
treatment in patients with moderately to
severely active ulcerative colitis. Benefits
were observed regardless of prior
advanced therapy exposure, including
among patients with experience across
multiple advanced therapies.

Tuesday,
October 13
10:30 AM – 4:00 PM CDT     

Poster P5727

Remission and Endoscopic Response with RINVOQ for Advanced and Difficult-to-Treat Crohn's Disease

Title

Description

Session Details

Real-World Outcomes of
Upadacitinib in Fistulizing
and Stricturing Crohn's
Disease Among Patients in
the Veterans Affairs Health
System

Real-world data from the Veterans Affairs
health system showed that 93.3% of
patients with fistulizing disease and 76.9%
of patients with stricturing disease who
remained on treatment achieved clinical
remission and corticosteroid-free remission
with upadacitinib.

Monday, October 12

10:30 AM – 4:15 PM CDT     

Poster P3482

Real-World Outcomes of
Upadacitinib in Isolated Ileal     
Crohn's Disease Among
Patients in the Department
of Defense Healthcare
System

New real-world data from the Department of      
Defense healthcare system demonstrated
clinical and endoscopic outcomes with
upadacitinib in patients with isolated ileal
Crohn's disease. At six months, 57% of
patients achieved clinical remission, 58%
achieved endoscopic response and 53.6%
achieved endoscopic remission.

Tuesday, October 13

2:35 PM – 2:45 PM CDT

Oral Presentation 39

About SKYRIZI® (risankizumab-rzaa)
SKYRIZI is an interleukin-23 (IL-23) inhibitor that blocks IL-23 by selectively binding to its p19 subunit. IL-23, a cytokine involved in inflammatory processes, is thought to be linked to a number of chronic immune-mediated diseases.i SKYRIZI is approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderately to severely active ulcerative colitis, plaque psoriasis, psoriatic arthritis and Crohn's disease.i 

On April 27, 2026, AbbVie announced submission of an application to the FDA seeking approval of SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.

SKYRIZI® (risankizumab-rzaa) U.S. Uses and Important Safety Informationi

SKYRIZI is a prescription medicine used to treat:

moderate to severe plaque psoriasis in adults and children 6 years of age and older who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). active psoriatic arthritis in adults and children 6 years of age and older. moderate to severe Crohn's disease in adults. moderate to severe ulcerative colitis in adults. IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction: fainting, dizziness, feeling lightheaded     
(low blood pressure)      swelling of your face, eyelids, lips, 
mouth, tongue, or throat      trouble breathing or throat tightness chest tightness skin rash, hives itching Infections:
SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including: fever, sweats, or chills  cough      shortness of breath    blood in your mucus 
(phlegm) muscle aches   warm, red, or painful 
skin or sores on your     
body different from
your psoriasis    weight loss diarrhea or stomach
pain burning when you 
urinate or urinating
more often than normal      Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions,
including if you:

have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?" have an infection that does not go away or that keeps coming back. have TB or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine. are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk. become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

Liver problems may happen while being treated for Crohn's disease or ulcerative colitis: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and at least up to 12 weeks of treatment, and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn's disease and ulcerative colitis include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, urinary tract infection, and rash.

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI (risankizumab-rzaa) is available in a 150 mg/mL prefilled syringe and pen, a 55 mg/0.37 mL prefilled syringe, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

Please click here for the Full Prescribing Information and Medication Guide.

About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3 and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

Upadacitinib is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus and vitiligo. The use of upadacitinib for these diseases is not FDA approved, and its safety and efficacy have not been established for these diseases.

RINVOQ® (upadacitinib) U.S. Uses and Important Safety Informationii

RINVOQ is a prescription medicine used to treat:

Adults with moderate to severe rheumatoid arthritis (RA) when 1 or more medicines called tumor necrosis factor (TNF) blockers have been used, and did not work well or could not be tolerated. Adults with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Adults with active ankylosing spondylitis (AS) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a TNF blocker medicine has been used, and did not work well or could not be tolerated. Adults with giant cell arteritis (GCA). Adults with moderate to severe ulcerative colitis (UC) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers. Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers. It is not known if RINVOQ is safe and effective in children with ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.

Adults and children 12 years of age and older with moderate to severe eczema (atopic dermatitis [AD]) that did not respond to previous treatment and their eczema is not well controlled with other pills or injections, including biologic medicines, or the use of other pills or injections is not recommended. It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.

It is not known if RINVOQ LQ is safe and effective in children with atopic dermatitis.

RINVOQ/RINVOQ LQ is a prescription medicine used to treat:

Children 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. Children 2 to less than 18 years of age with active psoriatic arthritis (PsA) when 1 or more medicines called TNF blockers have been used, and did not work well or could not be tolerated. It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)

What is the most important information I should know about RINVOQ<*>?

RINVOQ may cause serious side effects, including:

Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You should not start taking RINVOQ if you have any kind of infection unless your HCP tells you it is okay. If you get a serious infection, your HCP may stop your treatment until your infection is controlled. You may be at higher risk of developing shingles (herpes zoster). Increased risk of death in people 50 years and older who have at least 1 heart disease (cardiovascular) risk factor. Cancer and immune system problems. RINVOQ may increase your risk of certain cancers. Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in sunlight. Wear protective clothing when you are in the sun and use sunscreen. Increased risk of major cardiovascular (CV) events, such as heart attack, stroke, or death, in people 50 years and older who have at least 1 heart disease (CV) risk factor, especially if you are a current or past smoker. Blood clots. Blood clots in the veins of the legs or lungs and arteries can happen with RINVOQ. This may be life-threatening and cause death. Blood clots in the veins of the legs and lungs have happened more often in people who are 50 years and older and with at least 1 heart disease (CV) risk factor. Allergic reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking RINVOQ. Some of these reactions were serious. If any of these symptoms occur during treatment with RINVOQ, stop taking RINVOQ and get emergency medical help right away.  Tears in the stomach or intestines. This happens most often in people who take nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Get medical help right away if you get stomach-area pain, fever, chills, nausea, or vomiting. Low blood sugar (hypoglycemia) in people with diabetes. If you have diabetes, your HCP may tell you to check your blood sugar (glucose) more often during treatment with RINVOQ. Call your HCP if you have any problems with low blood sugar. Changes in certain laboratory tests. Your HCP should do blood tests before you start taking RINVOQ and while you take it. Your HCP may stop your RINVOQ treatment for a period of time if needed because of changes in these blood test results. Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

What should I tell my HCP BEFORE starting RINVOQ?

Tell your HCP if you:

Are being treated for an infection, have an infection that won't go away or keeps coming back, or have symptoms of an infection, such as: Fever, sweating, or
chills
Shortness of breath 
Warm, red, or
painful skin or
sores on your body Muscle aches
Feeling tired
Blood in phlegm 
Diarrhea or
stomach pain Cough
Weight loss
Burning when
urinating or
urinating more
often than normal      Have TB or have been in close contact with someone with TB. Are a current or past smoker. Have had a heart attack, other heart problems, or stroke. Have or have had any type of cancer, hepatitis B or C, shingles (herpes zoster), blood clots in the veins of your legs or lungs, diverticulitis (inflammation in parts of the large intestine), or ulcers in your stomach or intestines. Have other medical conditions, including liver problems, diabetes, low blood cell counts, chronic lung disease, HIV, or a weak immune system. Live, have lived, or have traveled to parts of the country, such as the Ohio and Mississippi River valleys and the Southwest, that increase your risk of getting certain kinds of fungal infections. If you are unsure if you've been to these types of areas, ask your HCP. Have recently received or are scheduled to receive a vaccine. People who take RINVOQ should not receive live vaccines. Are pregnant or plan to become pregnant. Based on animal studies, RINVOQ may harm your unborn baby. Your HCP will check whether or not you are pregnant before you start RINVOQ. You should use effective birth control (contraception) to avoid becoming pregnant during treatment with RINVOQ and for 4 weeks after your last dose. There is a pregnancy surveillance program for RINVOQ. The purpose of the program is to collect information about the health of you and your baby. If you become pregnant while taking RINVOQ, you are encouraged to report the pregnancy by calling 1-800-633-9110. Are breastfeeding or plan to breastfeed. RINVOQ may pass into your breast milk. Do not breastfeed during treatment with RINVOQ and for 6 days after your last dose. Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

Medicines for fungal or bacterial infections Rifampicin or phenytoin Medicines that affect your immune system If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.

What should I avoid while taking RINVOQ?

Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.

What should I do or tell my HCP AFTER starting RINVOQ?

Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw Pain or discomfort in your arms, back, neck, jaw, or stomach Shortness of breath with or without chest discomfort Breaking out in a cold sweat Nausea or vomiting Feeling lightheaded Weakness in one part or on one side of your body Slurred speech Tell your HCP right away if you have any signs or symptoms of blood clots during treatment with RINVOQ, including: Swelling Pain or tenderness in one or
both legs Sudden unexplained chest or
upper back pain Shortness of breath or difficulty
breathing Tell your HCP right away if you have a fever or stomach-area pain that does not go away, and a change in your bowel habits. What are other possible side effects of RINVOQ?

Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, swelling of the feet and hands (peripheral edema), increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).

A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.

Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your HCP.

These are not all the possible side effects of RINVOQ.

How should I take RINVOQ/RINVOQ LQ?

RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your HCP.

<*>Unless otherwise stated, "RINVOQ" in the IMPORTANT SAFETY INFORMATION refers to RINVOQ and RINVOQ LQ. 

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.

Please click here for the Full Prescribing Information and Medication Guide.

About AbbVie in Immunology 

AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For nearly 30 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of action and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.

Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 20+ immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.

Forward-Looking Statements 

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

i SKYRIZI [Package Insert]. North Chicago, IL: AbbVie Inc.
ii RINVOQ [Package Insert]. North Chicago, IL: AbbVie Inc.

SOURCE AbbVie

Coldcard, a company specializing in Bitcoin-only hardware wallets, reported that a phishing link appeared on its official X account on Sunday. The incident raised concerns given Coldcard’s longtime emphasis on security, including its use of offline two-factor authentication and tightly controlled account access procedures since 2017.

Account breach under investigationColdcard stated that it is currently investigating how the phishing link was posted from its verified X account. The post has now been removed. While the investigation is ongoing, the company emphasized that its only official website remains coldcard.com and warned users not to visit or engage with any other links that may appear to be from the company.

In response to the breach, Coldcard has reached out to X support and is conducting a comprehensive review of all account access records. The company has committed to sharing any further verified updates as they become available.

Users should avoid interacting with unauthorized links, and Coldcard’s only official online presence is at their website. The company is in contact with X and is auditing account access to ensure enhanced security.

The apparent compromise of a high-profile account with advanced authentication measures highlighted the ongoing vulnerability even among security-focused entities within the cryptocurrency sector. Coldcard reiterated that user vigilance is essential, particularly as cyber threats become increasingly sophisticated.

Impact of July exploits and market responseJuly 2026 became the second-worst month for cryptocurrency thefts this year, primarily due to a significant exploit targeting Coldcard users. According to data from DefiLlama, hackers made off with $247.4 million in digital assets during the month, behind only the $644 million stolen in April.

Galaxy Digital reported that the Coldcard-related attack accounted for the largest share, with at least $100 million in Bitcoin stolen from 7,300 wallets across three confirmed waves of attack. The company has also pointed to a suspected fourth wave of activity that could increase total losses to approximately $130 million.

DefiLlama’s hack tracker estimated the amount tied specifically to the Coldcard exploit at $115 million. The discrepancy in reported totals reflects ongoing efforts by security firms and blockchain analytics groups to precisely determine the scope of the theft.

The recurring losses underscore the persistent risk of phishing and account breaches, even for companies prioritizing robust security measures. As investigations continue, Coldcard pledged transparency with its community and ongoing audits to prevent further incidents.

Meme token market trends and risk monitoringAmid heightened security concerns, experts have noted the importance of carefully monitoring both technical transactions and market trends, especially as meme tokens attract massive attention. In the meme token market, an internet trend can transform into millions of dollars of interest within days. According to data shared by Fomo App, a trade involving “Niu Lai”—which turned an initial $99 investment into approximately $370,000, stands out as a striking example of this activity. In this market, tracking not only prices but also the timing and token choices of investors is crucial. Fomo App brings token discovery and trading together on a single platform, featuring social feeds, investor rankings, and trade notifications. Discover Fomo App to follow the world of meme tokens alongside investor activity.

The ongoing investigation and recent losses have spurred renewed calls for heightened awareness among crypto investors and service providers alike.

A whale investor has doubled Zcash holdings in the past two days to $66.75M. According to Arkham data, the large investor (address t1ZLg) bought $21.8M and $10.2M ZEC across Binance and Kraken, respectively, over the weekend. 

This effectively doubled the investor’s ZEC holdings from 24K to 54.4K (worth $66.75M) in two days. On-chain data revealed that the address began aggressive ZEC accumulation in mid-September. 

Source: Arkham The whale activity slowed for a while around 22nd-26th September but picked up aggressively at the end of the month. The activity slowdown coincided with the ZEC price peak near $1700. 

But the whale’s subsequent steady bids throughout October showed he was grabbing the ZEC’s discounted window as the price dropped by 34% in the past few days. This raises the question: Is there broader whale bidding to trigger ZEC price recovery? 

Zcash: Are other whales also buying the ZEC dip? Surprisingly, most whales were not bullish on ZEC, at least as of press time. According to CryptoQuant, the recent pullback was attracting ‘normal’ spot order sizes (grey bubble maps). 

Source: CryptoQuant  In most cases, big whale orders (denoted by green bubble maps) tend to coincide with easing pullbacks or triggering strong rebounds. This happened in March, August, and September. 

However, during the recent pullback, the indicator didn’t flag many big whale orders. As such, this could reduce the chances of a strong rebound or ZEC defending the $1000 support level. 

A similar picture was painted across the Futures market. According to Nansen, whale interest dropped by 14% in the past seven days across Hyperliquid’s derivatives market. However, smart money traders were up 134%. 

This indicates that some sophisticated players still view the recent discount window as a buying opportunity, like the whale that bought ZEC across Binance and Kraken. 

Source: Nansen But the Net Position Change was not green to underscore an overall bullish leaning. In other words, broader whale positioning was still somewhat cautious across the spot and derivatives market. 

Spot ZEC ETF extends weekly outflows And this cautious positioning is understandable ahead of this week’s U.S. inflation data (CPI), which could trigger another macro volatility and increase liquidation risks. 

In fact, even institutional investors have been in a risk-off mode since late September, as illustrated by two consecutive weeks of outflows from U.S. ZEC ETFs ($124M net outflows). 

Source: SoSo Value As such, the $1,100 and $1000 support levels could be retested or cracked if the bearish pressure deepens in the coming days. 

Overall, the recent 34% pullback seems like a great buying opportunity. However, the upcoming macro volatility still has whales and institutional investors on edge. 

Source: ZEC/USDT, TradingView  Final Summary Zcash whale doubled its ZEC holdings to $66.75M after buying the recent dip  Broader whale activity was weak, and spot ZEC ETF outflows hit $123M amid macro uncertainty 

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In AppLovin To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in AppLovin between February 12, 2026 and August 5, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - October 11, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AppLovin Corporation ("AppLovin" or the "Company") (NASDAQ: APP) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the generative AI video creative feature for the Company's AppLovin Ads platform was subject to significant development delays, making its release on the Company's timeline unlikely; (2) Defendants overstated the constancy with which AppLovin was improving its AI models; (3) for these reasons, among others, AppLovin had significantly overstated the benefits and reliability of the purportedly "virtuous cycle" and "compounding" value proposition that its AI models provided to customers and to the Company; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on July 13, 2026, when a Bank of America Securities analyst published a note reporting softer-than-expected e-commerce ad growth for the month of June, raising concerns over the rollout of AppLovin Ads to all advertisers. Bank of America Securities' review of publicly available e-commerce data showed "AppLovin's eCommerce footprint expanded at a slower pace in June", and the analyst concluded that the AppLovin Ads [general availability ("GA")] rollout enjoyed only a "muted . . . start." Accordingly, based on a "slower initial GA ramp", Bank of America Securities lowered its expectations of AppLovin's annual revenue.

Following publication of the note, AppLovin's stock price fell $64.13 per share, or 12.65%, to close at $442.85 per share on July 13, 2026.

Then, on August 5, 2026, AppLovin issued a press release announcing its financial results for the quarter ended June 30, 2026, and held a conference call to discuss the same. Among other items, AppLovin reported revenue of $1.92 billion, below consensus estimates of $1.94 billion. Defendants attributed their quarterly performance to their "pace of meaningful model improvement", which was "lighter than normal during the quarter." Defendants also revealed that their generative AI video tool was "still [a] work in progress."

On this news, AppLovin's stock price fell $82.13 per share, or 19.66%, to close at $335.67 per share on August 6, 2026.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding AppLovin's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the AppLovin class action, go to www.faruqilaw.com/APP or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Frequently Asked Questions (FAQ) for Investors Regarding the AppLovin Securities Class Action Lawsuit:

What is the AppLovin securities fraud lawsuit about?

The lawsuit alleges AppLovin misled investors about its AI technology, including development delays, the pace of AI model improvements, and the benefits and reliability of its AI-driven advertising platform.

Who may be eligible to participate in the lawsuit?

Investors who purchased or acquired AppLovin Corporation (NASDAQ: APP) securities between February 12, 2026 and August 5, 2026 may be eligible if they suffered losses.

What is a lead plaintiff, and how can I seek appointment?

A lead plaintiff represents the proposed class during the litigation. Eligible investors must file a motion with the court by November 16, 2026. Investors may participate without serving as lead plaintiff.

Why should investors contact Faruqi & Faruqi, LLP?

Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased AppLovin securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318333

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Uniswap has surpassed $6 billion in cumulative protocol fees, with nearly $147 million generated in the past 30 days alone, underscoring its dominance as the leading decentralized exchange.

@Uniswap has crossed a significant milestone, surpassing $6 billion in cumulative protocol fees. According to on-chain data, the decentralized exchange has now generated $6.07 billion in total fees since its launch, cementing its position as the dominant force in decentralized trading.

Fee Surge Fuelled by Multi-Chain Expansion The milestone has been driven in large part by a sharp rise in recent activity. $UNI generated close to $147 million in fees over the past 30 days alone, reflecting a period of sustained trading momentum across the protocol.

Much of that surge can be tied to Uniswap's expanding multi-chain footprint. More recently, Robinhood Chain has become a notable driver of volume.

Fee Switch Adds a New Economic Layer for $UNI Holders Beyond the raw fee figures, a structural shift is underway in how those fees flow.

For a protocol that has quietly processed trillions of dollars in trading volume, the $6 billion fee milestone is less a finishing line than a marker of how deeply embedded @Uniswap has become in on-chain finance.

Sources:
DefiLlama: Uniswap TVL, Fees, Revenue and Volume
CoinLaw: Uniswap Statistics 2026
Crypto Briefing: Uniswap Generates Nearly $23M in Protocol Revenue After Fee Switch Activation

U.S. spot Bitcoin exchange-traded funds (ETFs) recorded significant outflows this month, marking a notable shift in sentiment among crypto investors. Data from Decrypt’s ETF tracker shows these funds faced back-to-back redemptions, including a $484.9 million exit on Wednesday, their steepest daily withdrawal since June.

Bitcoin ETFs reverse course in OctoberDespite a brief recovery with $21.1 million in inflows on Friday, U.S. spot Bitcoin ETFs finished the first seven trading days of October with a net outflow of $386.3 million. The modest gain failed to compensate for large withdrawals earlier in the week, particularly following Wednesday’s sizable exit and an additional $244.1 million lost on Thursday.

Bitcoin ETFs provide a way for investors to participate in the digital asset market without directly holding cryptocurrencies or managing private wallets. The products mirror the price of Bitcoin and are traded on regular brokerage platforms, attracting both institutional and retail investors since their debut.

October began on a positive note, as the ETFs attracted a combined $292.6 million on the first two days. Another $118.8 million flowed in on October 6. However, these early inflows were overshadowed by the subsequent downturn, erasing previous gains for the month.

ETFOctober Net FlowsLargest Single-Day OutflowCumulative Net InflowsTotal Net AssetsBitcoin-$386.3 million-$484.9 million (Wed.)$57.6 billion$100.6 billionEthereum-$635 million-$201.9 million (Oct. 6)$13.2 billion$14.5 billionSolana-$24.8 million-$3.8 million (Fri.)$137.9 millionNot disclosedETF flows reflect shifting investor sentimentAfter a strong September, the landscape changed abruptly. In mid-September, following the U.S. Senate’s failed cloture vote on the Clarity Act, Bitcoin ETFs experienced a series of outflows. However, they quickly rebounded with nine straight sessions of inflows totaling roughly $3 billion, which returned year-to-date figures into positive territory for 2026.

Flows in and out of crypto ETFs have become a reliable gauge of market sentiment, as they reflect the willingness of investors to take on or shed digital asset exposure through regulated investment vehicles.

However, the reversal so far in October suggests caution and profit-taking may be returning to the market as uncertainty persists around regulatory and macroeconomic developments.

Ethereum and Solana ETFs deepen lossesEthereum ETFs have recorded a more severe downturn. The funds posted a $56.1 million outflow on Friday, extending their loss streak to nine consecutive trading days in October. During this period, cumulative withdrawals reached nearly $700 million, with the largest single-day loss of $201.9 million taking place on October 6. Despite these losses, Ethereum ETFs still hold $14.5 billion in total net assets and have attracted $13.2 billion in net inflows since their introduction.

Solana ETFs also faced negative flows this month, though on a much smaller scale compared to Bitcoin and Ethereum. Outflows for Solana ETFs totaled $3.8 million on Friday, the fifth straight day of net redemptions. The funds’ only inflow for October, $1.3 million, occurred on October 2. Overall, Solana ETFs have lost $24.8 million so far this month, while cumulative net inflows since launch stand at $137.9 million.

Solana, a blockchain known for its fast transaction speeds and lower fees compared to some other networks, continues to attract investor attention through ETF products, but recent flow data suggests more caution among holders.

Bitcoin ETFs, despite recent negative momentum, remain the largest by net inflow at $57.6 billion since launch and currently manage $100.6 billion in assets.

Mini dictionary: Cloture vote — A cloture vote is a procedure used in the U.S. Senate to end debate on a legislative issue and bring it to a final vote. Reaching cloture usually requires a supermajority, which can be a significant hurdle for passing contentious bills.

Shiba Inu's $SHIB memecoin is closing in on the 1.7 million Ethereum holder milestone, with its real-world holder base likely far larger once multichain addresses on Solana and Shibarium are included.

@Shibtoken's $SHIB memecoin is on the cusp of a significant community milestone. According to @etherscan, the token currently counts 1,698,001 holder addresses on Ethereum, putting it fewer than 2,000 wallets away from the 1.7 million mark.

Steady Growth Through September and October The climb to this level has been methodical rather than explosive. That pace continued into October, with

The steady accumulation is notable because it has come against a backdrop of subdued price action. For many observers, the persistence of wallet growth during quieter price periods is itself a signal of durable community interest.

It is worth noting a caveat on the numbers.

The Multichain Picture Makes 1.7M Look Conservative The Etherscan figure captures only Ethereum-native holdings. When other networks are factored in, $SHIB's true reach is considerably broader.

The token's footprint expanded further still in early October.

Taken together, the Ethereum count approaching 1.7 million is as much a floor as a ceiling. Once Shibarium and @Solana addresses are included, $SHIB's combined holder base already sits well above that figure, illustrating just how far the memecoin's reach now extends beyond its original chain.

Sources:
U.Today: 1,693,365 SHIB On-Chain Holders Reached
CoinTurk: Shiba Inu Surpasses 1.8 Million Holders Across Ethereum and Shibarium
CryptoNews: Shiba Inu Trading Volume Soars 171% After Launch on Solana

USD/SGD Forecast: Crédit Agricole Expects Further MAS Tightening Singapore Dollar support could strengthen as firm growth and rising inflation prompt another modest MAS policy tightening, says Crédit Agricole. Crédit Agricole expects Singapore to tighten monetary policy again on Wednesday, with technology-led growth and rising inflation supporting the case for a stronger currency despite the US Dollar's recent advance.

The Monetary Authority of Singapore's announcement is scheduled for 14 October.

Crédit Agricole's immediate currency outlook is more restrained, however, with 1.27 described as a strong near-term floor for USD/SGD while US interest-rate expectations continue to support the Dollar.

The latest official inflation release put August core inflation at 2.2%, up from 2% in July, with faster increases in services, retail goods and food prices.

Crédit Agricole strategist Eddie Cheung writes: "Singapore macro fundamentals continue to strengthen amid a global tech upcycle and foreign portfolio inflows, while the negatives from trade tensions have been less than expected."

Demand running above the economy's sustainable capacity would make it harder to absorb imported costs without broader price pressures.

Cheung writes: "At its July meeting, the MAS highlighted a projected widening of the positive output gap for 2026 as a whole-a situation we do not think has changed."

Inflation strengthens the case for another adjustment Crédit Agricole also highlights elevated oil prices as a continuing threat to imported costs.

MAS manages the Singapore Dollar against a basket of trading partners' currencies, using a faster appreciation path to restrain import prices and their spread into domestic inflation.

This is exchange-rate tightening, rather than a benchmark interest-rate rise.

Following April's tightening, MAS announced in its July policy decision: "MAS will therefore increase the rate of appreciation of the policy band very slightly."

It left the band's width and centre unchanged.

Cheung expects a similarly measured move: "Therefore, despite consecutive tightening, we think there is still scope for the MAS to tighten "very slightly" in October-the smaller increment introduced at its July meeting. Even if the MAS were to hold, we would expect a hawkish tilt."

US Dollar strength could delay Singapore Dollar gains Cheung writes: "The SGD has been a relative outperformer in Asia and is among the three regional currencies to have appreciated against the USD year-to-date, underpinned by Singapore's strong macro backdrop, foreign portfolio inflows and MAS tightening."

That assessment follows earlier ERUK coverage of the role of capital inflows and monetary policy in Singapore Dollar resilience.

Cheung estimates that the currency is already well into the upper half of the policy band: "MAS tightening should continue to keep the currency supported, with the SGD NEER currently positioned c.1.5% above the midpoint of the +/-2% policy band."

Those band parameters are the bank's estimates, rather than published MAS boundaries.

A firmer MAS stance can support Singapore's trade-weighted currency without ensuring that it rises against a strengthening US Dollar.

Cheung writes: "The greater risk for USD/SGD lies on the USD side, with the DXY rising to its highest level since Q225. We think the DXY could remain buoyed into end-2026 on the Fed rate hike dynamic before easing more substantially in 2027, leaving USD/SGD more rangebound around current levels."

Crédit Agricole's longer-term projection of USD/SGD at 1.25 by December 2027 allows for further Singapore Dollar gains as that US support fades.

The nearer 1.27 level is the bank's market assessment, not an official MAS boundary.

Cheung writes: "For now, 1.27 remains a strong floor, though we think this level could be tested as the USD weakens anew into 2027."

USD/SGD exchange rate FAQ When is the next MAS policy announcement?

The statement is scheduled for 14 October.

Does MAS tightening mean an interest-rate rise?

The expected adjustment is to the Singapore Dollar's appreciation path against a currency basket.

Is 1.27 an official USD/SGD limit?

No. It is Crédit Agricole's near-term market assessment. Its longer-term forecast is 1.25 by December 2027.

XAG/USD Forecast: UBS Recovery View Faces Yield Pressure Silver price rebound faces pressure from speculative selling and higher US real yields, Goldman Sachs warns, as UBS forecasts further gains in 2027. Silver prices rebounded on Friday, but UBS's forecast of $80 an ounce by September 2027 still depends on a substantial recovery from a market that has struggled to turn encouraging industrial indicators into sustained buying.

Spot silver closed near $60.83, up 2.2% on the day.

Robert Quinn, of Goldman Sachs FICC and Equities, writes: "Commitment of Traders encapsulating flows towards the end of September exhibited a large bearish turn in speculative positioning. Specifically, Managed Money, Other, and Non-Reportable net sold a combined $1.6bn from September 22nd - 29th, the largest weekly amount since February. Liquidation ($800mm) and new shorts ($800mm) contributed."

The estimate covers speculative positioning, rather than physical silver sales.

Half the selling closed bullish positions, while half established new bearish bets.

Image: Silver price in US dollars - three month chart Stronger industrial indicators have not overcome financial pressure Quinn's evidence for improving industrial prospects comes from equity-market indicators linked to sectors that use silver.

He writes: "Through early October, barometers for certain structural demand drivers improved. Over September 29th - October 7th, GS's Data Center and Solar equity baskets rose 4.2% and 2.4% respectively. Both maintained positive correlation with Managed Money gross long changes during the past 6 months."

These are equity-market indicators, rather than measurements of silver consumption.

During the same period, the financial conditions facing precious metals moved in the opposite direction.

Quinn writes: "However macroeconomic headwinds also proved formidable. Throughout the same time frame, US real rates edged higher and the Dollar increased (0.8%). Historically, stronger Dollar and real rate environments coincided with Managed Money gross long unwinds."

Higher inflation-adjusted yields increase the attraction of interest-bearing assets relative to silver, while a stronger Dollar raises the metal's cost for buyers using other currencies.

Quinn also identifies weakness in derivatives sentiment: "Thus in the end, the Silver price remained stuck with negative flows arguably persisting. Silver price fell 1.4%. Discretionary sentiment soured; consider normalized 25 delta put-call skew richened to the top 2 year decile. CTA selling also manifested, according to GS Futures Strategists' framework."

The options measure indicates stronger relative demand for downside protection, while Goldman's framework points to selling by systematic futures strategies.

UBS's recovery target faces an investment-demand test UBS's nearer forecast is $70 by December 2026, with further appreciation envisaged during 2027.

UBS has previously argued that higher gold prices and tighter physical conditions could support silver's recovery.

UBS said: "Silver, meanwhile, should benefit from higher gold prices and tighter near-term fundamentals."

More recent CFTC futures data for 6 October show managed-money investors still net long silver, but with that balance edging lower from the preceding week.

These futures-only figures cover a narrower group than Goldman's combined-category estimate.

Goldman sees a possible easing of one obstacle to recovery, rather than confirming that the selling has ended.

Quinn writes: "While acknowledging uncertainty over Middle East developments, note GS FX Research believes one pillar of Silver resistance, namely Dollar upside, could stall. Given stretched positioning on several pairs and recent Fed communication, the team is cautious on near-term Dollar prospects."

Silver price prediction, news FAQ What is UBS's silver forecast?

UBS forecasts $70 an ounce by December 2026 and $80 by September 2027.

Has Goldman Sachs issued an $80 silver target?

No. The $80 forecast belongs to UBS. Goldman's report analyses positioning and market pressures.

Was the $1.6bn selling a prediction?

No. Goldman estimates it occurred across the specified speculative categories during 22-29 September.

William Wallace McMullen, the Chairman of the Board, reported purchasing 34,514 shares of Mach Natural Resources LP (MNR +0.56%) on Sept. 15, 2026, according to a recent SEC Form 4 filing.

Premium Feature

Moneyball Superscore

55/100

Today's Change

(

0.56

%) $

0.06

Current Price

$

10.73

Transaction summaryMetricValueTransaction value~$389,000Shares purchased34,514Shares purchased (directly held)22,124Shares purchased (indirectly held)12,390Post-transaction shares (directly held)22,124Post-transaction shares (indirectly held)~74.9 millionPost-transaction value$838.8 millionTransaction value based on SEC Form 4 weighted average purchase price ($11.27); post-transaction value based on Sept. 15, 2026 market close ($11.20).

Key questionsWhich entities hold the company's indirect shares?
The majority of the equity is held by BCE Mach Aggregator LLC, which is managed by Bayou City Energy Management LLC, where McMullen serves as Managing Partner.How has the stock performed leading up to this acquisition?
The purchase at $11.27 per share followed a negative 16% return for the stock over the 12 months ending Sept. 15, 2026.What is the current scale of direct versus indirect ownership for the insider?
Direct holdings account for a minimal portion of the position at 22,124 shares, while indirect holdings through affiliated entities total ~74.9 million shares.What is the company's core operational focus?
Mach Natural Resources operates as an independent firm in the upstream energy sector, focusing on the development and production of crude oil and natural gas within the Anadarko Basin.Company OverviewMetricValueShare Price (as of market close 2026-09-17)$10.97Market Capitalization$1.80 billionRevenue (TTM)$1.40 billionNet Income (TTM)$243.60 millionCompany SnapshotMach Natural Resources LP operates as an independent upstream oil and gas exploration and production company, generating revenue through the acquisition, development, and production of crude oil, natural gas, and associated liquids primarily within the Anadarko Basin.The company's business model centers on identifying and acquiring acreage with development potential, executing capital-efficient drilling and completion programs, and monetizing hydrocarbon reserves through sales to major integrated oil companies and independent refiners.The company's primary customers consist of major integrated oil and gas companies, independent refiners, and midstream infrastructure operators that purchase crude oil, natural gas, and natural gas liquids produced from its Anadarko Basin operations.Mach Natural Resources LP is a mid-cap independent exploration and production company with a focused geographic footprint in the Anadarko Basin across Western Oklahoma, Southern Kansas, and the Texas Panhandle. The company generated $1.40 billion in revenue and $243.60 million in net income on a trailing twelve-month (TTM) basis, demonstrating operational profitability in the upstream energy sector. Founded in 2023 and headquartered in Oklahoma City, Oklahoma, with 840 employees, Mach pursues a disciplined development strategy targeting conventional and unconventional hydrocarbon accumulations within one of North America's most prolific sedimentary basins.

What this transaction means for investorsThere are many reasons an insider may sell shares, some of which have no reflection on their belief in the stock's direction, like having to pay a large personal expense or diversifying their holdings.

There is only one reason an insider, like McMullen, buys shares: they believe the stock price will rise.

By that investor's rule of thumb, McMullen's purchase of Mach shares is inherently bullish. On top of that, studies show that, more often than not, an insider purchase predicts a higher share price 30 days later.

The business has been performing well. Mach has a history of strong cash returns on capital invested and cash distributions. Over the past 5 years, it delivered an industry-leading cash return on capital invested (CROCI), averaging 35%, not only industry-leading, but also in the top 1% of all public companies in the U.S. It has also distributed an industry-leading distribution yield of 15% since 2024 through the first quarter of 2026. Wall Street consensus sees revenue rising to $1.43 bllion in the current fiscal year, a rise of 22%.

McMullen founded Mach Natural Resources and the entity that holds a large portion of its shares, Bayou City Energy Management, in 2015, and has been an energy industry analyst and investor since at least 2008. Clearly, he knows the U.S. oil and gas business very well and certainly has his finger on the pulse of Mach's business. It is bullish that he is a buyer.

McMullen's buying now suggests he expects Mach Natural Resources to deliver strong performance this year. High oil prices benefit U.S. producers like Mach, especially since its costs basically haven't changed -- oil prices are rising due to the Iran war, which doesn't affect U.S. production. That means the stock is worth investigating to see if you want to add it to your portfolio.

By You're currently following this author! Click to unsubscribe from email alerts.

Alexandr Wang's wild X feed seemed to lack any rhyme or reason, but the 29-year-old said it helped serve a broader purpose. Bloomberg/Getty Images Alexandr Wang said he had trouble focusing during recent Meta meetings.

On his mind: New memes to post about the company's popular new AI assistant.

"I would just like think of a meme and I'd be like 'Oh God, I have to get this out,'" Wang said in a recent interview with podcaster David Senra, adding that his coworkers were "somewhat surprised" at the buzz his posts were generating.

"It actually made an impact on growth," he said of the posts, "which is kind of hilarious."

Much has been said about Meta's chief AI officer and his chaotic X feed, which the 29-year-old has crammed with occasionally off-color yet invariably eccentric references to Muse, Meta's personal AI assistant that sent the company's stock soaring and redefined the market for AI tools.

In his interview with Senra, though, Wang said that his often spur-of-the-moment posts served a broader goal — to make Meta "cool again."

"Despite having like these incredible pieces of cultural software like Instagram and Facebook, historically, Meta was not cool," he said. "I remembered that the internet rewards risk."

After launching on September 8, Muse shot to the top of Apple's app store 10 days later, surpassing ChatGPT. Meta says Muse can help users research, fill out forms, buy items online, book restaurant reservations, find a dog sitter, and connect with services such as email, calendars, Spotify, Instagram, and OpenTable.

The app marked Meta's first successful breakthrough in AI tech, after its Llama and Spark LLM models failed to find niches already filled by widely used models from OpenAI and Anthropic.

With Muse, Meta found a largely untapped gold mine — though competing AI agents from OpenClaw and Instinct already existed in Silicon Valley circles. Muse, however, had the advantage of coming from a popular company with several billion potential customers already signed up on Instagram and Facebook.

And the internet, weary of staid pronouncements from CEOs who were perhaps once cool but are now entering their 40s (Mark Zuckerberg is 42), welcomed the boundless energy of a young executive newly endowed with power in the AI era.

"It was a lot of fun," Wang said. "There were like a few tweets where I just didn't think that much about it and just said, 'Fuck it, post.'"

Business Insider wants to know, by the way, how you're using personal AI agents. Take our survey below!

Read next

Truman Dickerson You're currently following this author! Click to unsubscribe from email alerts.

Truman Dickerson is the Weekend News Fellow at Business Insider, based in New York City. He covers trending tech and business news. He previously reported for The Boston Globe's Express Desk. He graduated from Boston University, where he served as editor in chief of The Daily Free Press, BU's student-run newspaper.Contact him at [email protected]

Meta Facebook Mark Zuckerberg More

It's a good time to be a copper investor. Copper is needed for data centers, and data centers are proliferating across the U.S. Copper is needed for wind turbines, too, and electric vehicles reportedly use up to four times as much copper as traditional cars. The International Energy Agency (IEA) is estimating that global copper demand will jump some 17%, from 26.7 million tonnes in 2024 to 31.3 million tonnes by 2030.

Could investing in a copper-mining company set you up for life? How about Freeport-McMoRan (FCX +3.58%)? It describes itself as "dedicated to positively contributing to society by supplying the world with copper -- Responsibly, Reliably and Relentlessly." It sports a portfolio of long-lived copper assets around the world. (It also produces gold and molybdenum, but its primary focus is on copper.)

Image source: Getty Images.

Indeed, its portfolio features the Grasberg mine in Indonesia -- the world's second-largest copper mine and largest gold mine. In 2025, Freeport-McMoRan produced 3.4 billion pounds of copper, accounting for about 70% of U.S. refined copper production.

Premium Feature

Moneyball Superscore

68/100

Today's Change

(

3.58

%) $

2.55

Current Price

$

73.69

It clearly looks like a great buy, right? Well, maybe not. Its valuation is on the steep side. Its price-to-earnings (P/E) ratio was recently 35, well above the five-year average of 22, and its price-to-sales ratio of 4.0 was also well above the five-year average of 2.6. It's smart to buy into healthy and growing companies, but you don't want to do so at a high price.

I would be careful about investing in the company at recent levels. The more overvalued a stock is, the less likely it is to set you up for life.

You might instead add it to your watch list, waiting for a pullback -- because it does seem like demand for copper is growing, and copper specialists should profit from that. Or maybe start a small position in it if you're really bullish on it. (There are other copper-related companies to learn about and consider.)

Consider copper-focused exchange-traded funds (ETFs), too -- such as the Global X Copper Miners ETF, which encompasses 40 companies, including Freeport-McMoRan.

Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Global chip equipment spending is surging toward $144 billion, yet one of the industry's biggest names is growing at a fraction of its rivals' pace, putting its long-term position in the market under serious pressure.

Worldwide wafer fabrication equipment spending is projected to increase 23.1% to $143.9 billion in 2026, following a record $116.9 billion in 2025 Applied Materials’ global equipment market share declined from 20.0% in 2024 to 17.9% in 2025, while Lam Research, KLA and ASML gained share Applied Materials’ equipment revenue increased only 1.0% during the first half of 2026, compared with double-digit growth at its three major competitors, raising questions about its ability to recover market share Applied Materials Faces a Market Share Challenge The global semiconductor equipment industry is experiencing another major expansion, supported by artificial intelligence infrastructure investment, high-bandwidth memory, advanced logic manufacturing and increasingly complex semiconductor architectures. Worldwide wafer fabrication equipment (WFE) sales are projected to increase 23.1% to $143.9 billion in 2026, following a record $116.9 billion in 2025. The forecast reflects continued investment in the manufacturing technologies required to support the next generation of semiconductor devices.

However, the expansion is not benefiting every equipment manufacturer equally. Applied Materials (AMAT | AMAT Price Prediction), historically one of the industry’s largest and most diversified suppliers, has experienced a significant deterioration in its global market share. Its competitors, including Lam Research (LRCX), KLA (KLAC) and ASML (ASML), have demonstrated substantially stronger revenue growth during the latest first-half comparisons.

According to proprietary data from The Information Network, Applied Materials’ global WFE market share declined from 20.0% in 2024 to 17.9% in 2025, representing a loss of 2.1 percentage points. During the same period, Lam Research increased its share from 9.1% to 11.2%, KLA advanced from 7.9% to 8.2%, and ASML recovered from 22.4% to 23.0%.

The concern for investors is that Applied Materials’ equipment revenue increased only 1.0% during the first half of 2026 compared with the corresponding period in 2025. This contrasts sharply with the growth recorded by its major competitors and raises questions about whether Applied Materials can participate proportionately in the industry’s projected expansion.

The distinction is particularly important because the five largest semiconductor equipment manufacturers collectively account for a substantial majority of global WFE revenue. Their combined revenue is projected to increase from approximately $83.2 billion in 2025 to $113.6 billion in 2026, representing growth of approximately 36.5%. This is considerably faster than the projected 23.1% expansion of the worldwide market, suggesting that the industry’s largest suppliers could collectively increase their market share.

For Applied Materials, however, the question is whether its own revenue performance will improve sufficiently to participate in that shift.

A Continuing Shift in Semiconductor Equipment Market Share Applied Materials’ market share deterioration is not an isolated development. Its global WFE market share reached 22.2% in 2016, declined to 18.1% in 2019, and subsequently recovered to approximately 20.0% in 2022. That recovery has not been sustained, with its share falling to 17.9% in 2025.

The recent decline is particularly significant because the semiconductor equipment market has benefited from increased investment in advanced logic, memory and packaging technologies. Applied Materials participates in many of these markets through deposition, materials engineering, ion implantation and other process technologies. Nevertheless, its overall market share performance indicates that its revenue growth has not consistently matched the industry’s expansion.

According to Table 1, Applied Materials’ global WFE market share remained approximately stable between 2023 and 2024 before declining sharply in 2025. Lam Research experienced the opposite trajectory, increasing from 8.5% in 2023 to 11.2% in 2025. KLA also gained share, while ASML recovered in 2025 after declining in 2024. The 2026 projections illustrate the market share recovery that would be possible if the manufacturers achieve their respective full-year revenue forecasts.

Table 1. Global Semiconductor Equipment Market Share, 2023–2026 Company 2023 2024 2025 2026 Forecast Applied Materials (AMAT) 19.9% 20.0% 17.9% 20.4% Lam Research (LRCX) 8.5% 9.1% 11.2% 13.2% KLA (KLAC) 7.4% 7.9% 8.2% 8.3% ASML (ASML) 24.2% 22.4% 23.0% 25.2% Source: The Information Network. Historical market shares through 2025; 2026 projections calculated from supplied company revenue growth forecasts and worldwide WFE growth of 23.1%. The projected improvement in Applied Materials’ market share from 17.9% in 2025 to 20.4% in 2026 would require a substantial acceleration in its equipment revenue growth. Its full-year revenue projection assumes approximately 40% growth, a sharp contrast with the 1.0% increase recorded during the first half of 2026.

This difference between projected annual growth and actual first-half performance is central to evaluating the company’s outlook. The market share forecast demonstrates what Applied Materials could achieve under a strong recovery scenario, but its recent revenue performance provides limited evidence that such an acceleration is already underway.

The forecasts also indicate that the largest equipment manufacturers could capture a greater proportion of worldwide spending. However, these projections depend on the companies achieving their respective revenue targets and on maintaining consistent definitions between reported equipment revenue and the global WFE market.

First-Half 2026 Revenue Growth Reinforces the Competitive Divergence The competitive differences become more apparent when examining semiconductor equipment revenue growth during the first halves of 2025 and 2026.

Applied Materials’ equipment revenue increased 8.7% during the first half of 2025 compared with the corresponding period in 2024. However, its full-year 2025 equipment revenue increased only approximately 2%, coinciding with its 2.1-percentage-point market share decline.

During the first half of 2026, Applied Materials’ equipment revenue growth slowed further to just 1.0%. In contrast, Lam Research, KLA and ASML continued to report substantially stronger growth.

According to Table 2, Lam Research’s equipment revenue increased 23.3% during the first half of 2026, compared with 12.6% for KLA and 13.3% for ASML. The three manufacturers averaged 16.4% growth, substantially exceeding Applied Materials’ performance.

Table 2. Semiconductor Equipment Revenue Growth, First-Half Comparisons Company 1H 2025 vs. 1H 2024 1H 2026 vs. 1H 2025 Applied Materials (AMAT) +8.7% +1.0% Lam Research (LRCX) +41.8% +23.3% KLA (KLAC) +30.7% +12.6% ASML (ASML) +30.1% +13.3% Competitor Average +34.2% +16.4% Source: The Information Network. Competitor average represents the unweighted average of Lam Research, KLA and ASML Although revenue growth slowed across all four manufacturers, Applied Materials’ performance remained substantially weaker than that of its competitors. Its first-half 2026 growth was only a small fraction of the increases recorded by Lam Research, KLA and ASML.

This divergence raises questions about the assumptions underlying the company’s projected full-year recovery. If Applied Materials is to increase its equipment revenue approximately 40% in 2026, its second-half performance would need to accelerate dramatically from the first-half growth rate.

That acceleration is mathematically possible, particularly if equipment shipments and customer investments are heavily weighted toward the latter part of the year. However, investors should distinguish between a forecast that assumes strong second-half growth and evidence that such growth is materializing.

The company’s recent market share deterioration also illustrates the consequences of falling behind the overall industry. Applied Materials lost 2.1 percentage points of global WFE share in 2025 despite reporting positive equipment revenue growth. If its 2026 performance remains below the projected 23.1% expansion of worldwide WFE spending, further market share erosion would follow.

Why Lam Research, KLA and ASML Are Better Positioned The semiconductor equipment market is undergoing a structural transition as chipmakers adopt gate-all-around transistors, advanced DRAM architectures, higher-layer-count 3D NAND and increasingly sophisticated packaging technologies. These developments increase the importance of specific manufacturing processes, creating opportunities for suppliers with strong positions in those categories.

Lam Research benefits from growing etch and deposition requirements in advanced memory and logic manufacturing. Increasing NAND layer counts, more demanding DRAM structures and new transistor architectures require sophisticated processing technologies. Lam’s global WFE market share increased from 8.5% in 2023 to 11.2% in 2025, demonstrating its ability to capture a larger portion of equipment spending. Its first-half 2026 revenue growth of 23.3% also provides evidence of continued competitive momentum.

KLA benefits from the increasing importance of semiconductor inspection, metrology and process control. Advanced manufacturing requires tighter process tolerances and more sophisticated defect detection to maintain acceptable yields. KLA’s global market share increased from 5.9% in 2018 to 8.2% in 2025, reflecting the growing importance of these capabilities. Its competitive position becomes increasingly valuable as semiconductor structures become more difficult to manufacture.

ASML occupies a different position through its dominance in extreme ultraviolet lithography. The transition toward advanced logic nodes increases demand for sophisticated lithography systems, supporting ASML’s long-term growth. Its global WFE market share increased from 15.5% in 2015 to 23.0% in 2025, although annual results fluctuate with equipment delivery schedules and customer investment.

Applied Materials also participates in many of the technologies driving equipment demand. Its deposition, materials engineering and other process technologies remain essential to semiconductor manufacturing, while advanced packaging provides additional opportunities. Nevertheless, the company’s recent revenue performance suggests that these opportunities have not yet translated into growth comparable to that of its principal competitors.

For investors, the distinction between participation in growing markets and capturing a larger share of those markets remains critical. Companies with strong positions in the most rapidly expanding manufacturing processes may benefit disproportionately from the current equipment investment cycle.

China’s Domestic Equipment Expansion Adds Competitive Pressure Applied Materials also faces growing competition from Chinese semiconductor equipment manufacturers, which are expanding their presence in deposition, etch, cleaning and other manufacturing processes.

According to The Information Network, six leading Chinese equipment manufacturers recorded average first-half 2026 revenue growth of 35.6%, compared with 11.4% for seven major non-Chinese manufacturers. These figures represent unweighted company averages rather than aggregate market growth rates, but they illustrate the momentum of China’s domestic equipment industry.

Piotech recorded first-half revenue growth of 49.1%, followed by Hwatsing at 35.6%, ACM Research at 35.2%, AMEC at 34.9%, Skyverse at 34.0% and NAURA at 24.9%. Their expansion reflects continued investment in domestic semiconductor manufacturing capabilities and efforts to increase the use of locally manufactured equipment.

However, Chinese manufacturers still account for less than 10% of worldwide semiconductor equipment revenue. Their rapid growth therefore cannot independently explain major market share shifts among the industry’s largest international suppliers. Those changes also reflect differences in technology exposure, product demand and the distribution of capital spending across manufacturing processes.

For Applied Materials, the competitive challenge comes from both directions. Chinese suppliers are expanding their participation in domestic equipment spending, while established international manufacturers continue to benefit from strong positions in critical advanced manufacturing technologies.

Investor Takeaway The semiconductor equipment industry remains one of the principal beneficiaries of artificial intelligence infrastructure investment, advanced memory manufacturing and continued semiconductor technology development. With worldwide WFE revenue projected to increase 23.1% to $143.9 billion in 2026, the industry offers substantial opportunities for manufacturers capable of capturing incremental capital spending. However, The Information Network’s historical data demonstrate that Applied Materials has struggled to maintain its competitive position. Its global market share declined from 20.0% in 2024 to 17.9% in 2025, while Lam Research, KLA and ASML all gained share during that year.

The first-half 2026 revenue comparisons raise additional concerns. Applied Materials’ equipment revenue increased just 1.0%, compared with 23.3% for Lam Research, 12.6% for KLA and 13.3% for ASML. Although the full-year projections indicate that Applied Materials could recover market share to approximately 20.4% if its equipment revenue increases 40%, achieving that outcome would require a substantial acceleration during the remainder of 2026. The discrepancy between actual first-half performance and the projected full-year recovery is therefore a critical issue for investors evaluating the company’s competitive position.

For investors, the semiconductor equipment industry’s expansion remains attractive, but company selection is increasingly important. Lam Research’s recent market share gains and revenue growth make it particularly well positioned, while KLA’s process control capabilities and ASML’s lithography leadership provide important competitive advantages. Applied Materials remains an important industry supplier, but its investment case increasingly depends on demonstrating that its broad technology portfolio can generate revenue growth comparable to the overall market. Until that improvement becomes evident, the possibility of further market share erosion remains an important consideration in evaluating the stock.

Contact [email protected] for any questions or corrections.

Peter Beck has a bold plan to turn Rocket Lab into a self-launching tier-1 space power, but reaching the price target that would prove him right requires several high-stakes moves to land perfectly.

Rocket Lab (NASDAQ:RKLB | RKLB Price Prediction) has built a track record of building and flying rockets. Now its founder and CEO, Peter Beck, wants a much bigger role. When he announced the Iridium Communications (NASDAQ:IRDM) acquisition, Beck said the deal sets up Rocket Lab as “a self-launching, tier-1 space power that will deliver critical communications capability to millions of users worldwide.” Iridium stockholders approved the deal in September.

The stock has fallen behind the business. Shares are down 2.22% year to date at $68.21, even though Q2 revenue rose 62% to a record. Several things need to go right for Rocket Lab to reach $125 per share in 2027.

Wall Street Already Sees 56% Upside The average analyst target is $106.57, which implies 56% upside. Ratings stand at 4 Strong Buy, 12 Buy, 4 Hold and zero Sell. Rocket Lab has exceeded revenue estimates in each of the last 4 quarters. Q2 EPS of -$0.08 missed the -$0.0767 estimate, but that figure included $8.58M in acquisition costs. Backlog reached $2.36B, up 137%, and Q3 revenue guidance is $250M-$265M.

Here’s What It Takes to Reach $125 Rocket Lab isn’t profitable yet, so price-to-sales is the better metric. Shares trade at 56.7x trailing sales. At $125, that multiple would rise to roughly 104x. That’s a big premium, but it is close to the 93x investors pay for SpaceX (NASDAQ:SPCX). SpaceX posted $7.81B in Q2 revenue, and $648M of that came from launch services. Launch alone is a large market.

How Rocket Lab might reach $125.

Neutron’s debut: Neutron is Rocket Lab’s reusable medium-lift rocket, and its starting price of $50 million to $55 million puts it head-to-head with Falcon 9. CNBC reported that management expects boosters to fly 10 to 20 times each. Beck put it bluntly: “Neutron demand is just not a concern.” Defense spending: The FY2027 budget includes $17.9 billion for Golden Dome. Rocket Lab already holds an $816M Space Development Agency contract and a $397M Flatellite award. Iridium: Iridium generated more than $870 million in annual revenue, and the deal is expected to close in mid-2027. Margin gains: Non-GAAP gross margin rose to 41.5% from 36.9%. The adjusted EBITDA loss shrank to $8.8M from $27.6M. The Neutron launch can change the dynamic and make Rocket Lab a viable challenger to SpaceX. With the cost per launch expected to fall from around $130 million to $50 million as volume ramps higher, it would make Rocket Lab a profitable alternative to its rival.

Key risks: Neutron’s maiden year-end launch window is narrowing, and Rocket Lab raised $1.53B by selling stock in the first half of 2026, which dilutes existing shareholders.

Shares Topped $125 Within the Past Year Reaching $125 requires an 83% gain. The stock has already traded above that level: its 52-week range runs from $37.57 to $151, a swing of about 302%. With a beta of 2.938, Rocket Lab is likely to move far more than the overall market. Over five years, shares have gained 363.7%.

$125 Is a Stretch, but Within Reach Hitting $125 would take an 83% gain in 2027. Analysts already see 56% upside, the backlog keeps hitting records, and Neutron could start competing directly with SpaceX. Execution risk is real. Still, returns at this level are unlikely every year, and this is the model for how Rocket Lab could deliver outsized returns in 2027.

Contact [email protected] for any questions or corrections.

SummaryEQT Corporation, the largest U.S. natural gas producer, is well-positioned for growth amid record demand and robust infrastructure.EQT's vertical integration, contiguous land holdings, and economies of scale drive operational efficiency and competitive advantage.Key catalysts include the Blackline Midstream acquisition, Mountain Valley Pipeline expansions, and long-term data center supply contracts.I recommend a BUY rating, citing strong project economics, resilient demand outlook, and disciplined, contract-backed growth strategy.Suphanat Khumsap/iStock via Getty Images

EQT Corporation (EQT) is the largest natural gas producer in the United States. Its extraction operations are focused almost entirely on the Appalachian Basin, although 49% of its production is sold outside this region, primarily in the Gulf

32 Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Mexican Peso Outlook UBS and Crédit Agricole Split Over 2027 Direction The Mexican Peso could strengthen or surrender ground against the US Dollar in 2027, with UBS and Crédit Agricole taking opposing currency views. UBS and Crédit Agricole expect the Mexican Peso to move in opposite directions over the coming year, setting markedly different forecasts for the same September 2027 horizon.

UBS projects USD/MXN at 17.20, against Crédit Agricole's 18.75.

The comparison captures a disagreement over the Peso's direction, with the exchange rate close to 18 in both banks' recent forecast documents.

Against that approximate reference, UBS's projection implies roughly 4.7% Peso appreciation, while Crédit Agricole's points to a decline of around 4%.

UBS retains its recovery view after a near-term setback UBS's optimism survives a recent reassessment of the Dollar's strength.

As Exchange Rates UK reported in our coverage of UBS's revised Peso outlook, the bank raised its nearer-term USD/MXN projection while retaining its September 2027 recovery target.

That earlier analysis argued that the Peso could continue to attract investors seeking interest income, even with a smaller advantage over US rates.

UBS said: "Despite the narrower US-Mexico rate differential, the global backdrop remains supportive for carry strategies given still benign financial conditions."

Investors funding Peso holdings in another currency must weigh the interest earned against both their financing costs and the risk of exchange-rate losses.

Mexico's central-bank overnight policy rate stands at 6.50%.

A weaker Peso can offset part or all of the additional interest income, particularly if US yields also rise and narrow Mexico's relative appeal.

UBS's earlier assessment identified a sharp US slowdown and disputes over the US-Mexico-Canada trade agreement as risks to the currency.

Those risks expose a tension in the Peso's relationship with its northern neighbour: a strong US economy can support Mexican activity, while higher US interest rates can make Dollar assets harder to compete with.

Crédit Agricole expects a less favourable outcome Crédit Agricole's higher USD/MXN target fits a more selective approach to emerging-market currencies.

In earlier coverage of its Latin American currency outlook, the bank distinguished potential gains elsewhere in emerging markets from a weaker assessment of the Mexican and Colombian Pesos.

The bank said: "We do not expect a full-fledged appreciation of EM FX vs the USD."

Its latest forecast leaves the Mexican Peso weaker by September 2027 even though the bank expects the Dollar to lose ground against some other currencies over that period.

The banks also differ on Mexico's economic prospects.

UBS forecasts 2% growth in 2027, against Crédit Agricole's 1.2%, giving the Swiss bank a stronger domestic growth outlook alongside its more favourable currency projection.

USD/MXN exchange rate FAQ Will the Mexican Peso rise or fall vs the US Dollar in 2027?

The banks disagree. UBS expects appreciation by September 2027, while Crédit Agricole expects depreciation.

What are their USD/MXN targets?

For September 2027, UBS forecasts 17.20 and Crédit Agricole forecasts 18.75.

Does a lower USD/MXN mean a stronger Peso?

Yes. Each US Dollar would buy fewer Mexican Pesos.